Business
Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\t- MSPrecise next generation sequencing assay supports identification of multiple sclerosis patients with 84% accuracy -\n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n\n\n\t- Results from this study were not combined with oligoclonal banding (OCB) - \n\n\t- MSPrecise performs well in identifying MS among a broad cohort of potential neurological diseases -\n\n\tSAN FRANCISCO and GENEVA, July 29, 2015 (GLOBE NEWSWIRE) -- Amarantus Diagnostics, a neurology-focused diagnostics company developing diagnostic tests for multiple sclerosis and Alzheimer's disease and a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), announced the publication of data on its next generation sequencing (NGS) molecular diagnostic test for multiple sclerosis, MSPrecise®. The paper entitled, \"MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing,\" has been published in the Elsevier journal GENE.\n\n\tMSPrecise is a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS). MSPrecise utilizes next-generation sequencing to measure DNA mutations found in rearranged immunoglobulin genes in immune cells isolated from cerebrospinal fluid. A blood based version of the test is in development.\n\n\t\"Given the early misdiagnoses that often occur with multiple sclerosis, physicians have an increasing need for new methods to accurately diagnose their patients,\" said Colin Bier, Chief Development Officer of Amarantus Diagnostics. \"MSPrecise scoring is a powerful approach to aid clinicians in this task. In this study completed in 2013 and now reported in 'GENE,' there is an overall MSPrecise accuracy of 84% in identifying RRMS patients or patients that will develop RRMS, which represents a huge benefit to physicians. In early 2015, Amarantus reported data from a later study that showed a significant increase in the accuracy of MSPrecise when adding oligoclonal banding (OCB) to the algorithm. We intend to publish those data combining MSPrecise and OCB in the near future.\"\n\n\tPrevious studies demonstrated that cerebrospinal fluid-derived (CSF) B cells from early relapsing-remitting multiple sclerosis (RRMS) patients that express a VH4 gene accumulate specific replacement mutations that can be ...